Home » Stocks » BIIB

Biogen Inc. (BIIB)

Stock Price: $274.04 USD 1.93 (0.71%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $272.50 -1.54 (-0.56%) May 7, 7:39 PM
Market Cap 41.26B
Revenue (ttm) 12.60B
Net Income (ttm) 3.01B
Shares Out 151.90M
EPS (ttm) 19.29
PE Ratio 14.21
Forward PE 14.93
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $274.04
Previous Close $272.11
Change ($) 1.93
Change (%) 0.71%
Day's Open 270.66
Day's Range 270.66 - 279.20
Day's Volume 936,142
52-Week Range 223.25 - 363.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The past six months have seen a huge rotation out of traditional momentum growth stocks to cyclical and value stocks as the bull market ages.

Other stocks mentioned: CTXS, FCX, SPOT
3 days ago - 24/7 Wall Street

Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug is being developed in collaboration with Biog...

6 days ago - Benzinga

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for...

1 week ago - GlobeNewsWire

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today released its 2020 Year in Review, which outlines the company's ongoing leadership actions over the past year, includ...

1 week ago - GlobeNewsWire

The past six months have seen a huge rotation out of traditional momentum growth stocks to cyclical and value stocks as the bull market ages.

Other stocks mentioned: CTXS, FCX, SPOT
1 week ago - 24/7 Wall Street

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Other stocks mentioned: AVXL, AXSM, JAZZ, SAVA
2 weeks ago - Zacks Investment Research

Biogen Inc (NASDAQ: BIIB) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs. Net income fell to $410.2 millio...

2 weeks ago - Benzinga

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

2 weeks ago - Zacks Investment Research

It's partially because expectations weren't very high in the first place.

2 weeks ago - The Motley Fool

The shares of Biogen Inc (NASDAQ:BIIB) were last seen down 3.9% at $259.23, even after the pharmaceutical concern posted first-quarter earnings of $5.34 per share, which topped analysts' estimates.

2 weeks ago - Schaeffers Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 5.53% and 0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Shares of Biogen (NASDAQ:BIIB) moved higher by 1.4% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 41.58% year over year to $5.34, which beat...

2 weeks ago - Benzinga

Biogen Inc reported a 70.7% fall in first-quarter profit on Thursday, as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic versions.

2 weeks ago - Reuters

Biogen (NASDAQ:BIIB) unveils its next round of earnings this Thursday, April 22. Here is Benzinga's everything-that-matters guide for the earnings announcement.

2 weeks ago - Benzinga

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important upda...

Other stocks mentioned: AZN, JNJ, MRNA, PFE, SRPT, VRTX
2 weeks ago - GuruFocus

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.

2 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA® (nusinersen) clinical development program aimed at optimizing outcomes for peo...

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the A...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that China's National Medical Products Administration (NMPA) has approved TECFIDERA® (dimethyl fumarate) f...

3 weeks ago - GlobeNewsWire

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer's disease investigational...

3 weeks ago - GlobeNewsWire

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

3 weeks ago - Zacks Investment Research

Sage Therapeutics unveiled promising results for its Biogen-partnered essential tremors treatment known as SAGE-324 on Monday, but Sage stock tripped on worse-than-expected side effects. The post Sage S...

3 weeks ago - Investors Business Daily

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major molecule...

3 weeks ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatmen...

Other stocks mentioned: SAGE
3 weeks ago - Business Wire

Upcoming events could send these stocks screaming higher or lower.

Other stocks mentioned: ITOS, NVAX
4 weeks ago - The Motley Fool

A few months ago, GuruFocus launched the "baskets" feature, which allows users to place stocks in one of four virtual baskets based on their level of interest:

Other stocks mentioned: AAPL, BABA, INTC, TSLA, VMW
1 month ago - GuruFocus

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the nomination of Maria C. Freire, Ph.D. and William D. Jones to stand for election to the company's board...

1 month ago - GlobeNewsWire

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ABBV, ACAD, ALXN, AZN, BNTX, CRSP, EDIT ...
1 month ago - Investors Business Daily

Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.

Other stocks mentioned: GILD, SAGE, VRTX
1 month ago - Investors Business Daily

Biogen Inc (NASDAQ: BIIB) and Bio-Thera Solutions Ltd have entered into a commercialization and license agreement to develop, manufacture, and commercialize BAT1806, a proposed biosimilar referencing Ge...

1 month ago - Benzinga

CAMBRIDGE, Mass. and GUANGZHOU, China, April 08, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a commercialization ...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of...

1 month ago - GlobeNewsWire

Experts worry about how trial data was analyzed.

1 month ago - The Motley Fool

When stocks are punished, it's not always for a good reason.

Other stocks mentioned: CCL, CCR, LL, SAGE, SKY, VIAC
1 month ago - GuruFocus

Biogen Inc.'s (NASDAQ:BIIB) management and shareholders are keeping their fingers crossed that the Food and Drug Administration rules favorably on the company's controversial Alzheimer's drug. The decis...

1 month ago - GuruFocus

Mother with ALS seeks life-saving drug from Biogen

YouTube video

CNBC's Meg Tirell joins ‘The News with Shepard Smith' to report on one mother who is seeking help from an experimental drug to treat her terminal illness.

1 month ago - CNBC Television

After previously exiting a position in the fourth quarter of 2020, Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a new 5.03% stake in Tricida Inc. (NASDAQ:TCDA) earlier this...

Other stocks mentioned: AZN, BHC, BMY, LLY, MRK, TCDA
1 month ago - GuruFocus

Biogen's future isn't only wrapped up in Alzheimer's treatment aducanumab, an analyst said Thursday. He identified two low-probability events that could stoke Biogen stock.

1 month ago - Investors Business Daily

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Other stocks mentioned: FATE, GILD, JNJ, ORTX, SANA, SGMO
1 month ago - GuruFocus

It's been a long time coming, but the great value comeback appears to be underway.

Other stocks mentioned: AAPL, AMZN, DHI, HEAR, MSFT, SENEA
1 month ago - GuruFocus

They're making headway into tomorrow's hot markets.

Other stocks mentioned: PFE, REGN
1 month ago - The Motley Fool

They'll determine short-term and long-term stock performance.

1 month ago - The Motley Fool

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have grown their book value per share over the past decade through March 11.

Other stocks mentioned: COO, HUM, UHS
1 month ago - GuruFocus

These 4 stocks to buy have good fundamentals, are attractive from a valuation perspective and can provide safety in a volatile 2021. The post 4 Stocks To Buy Ready To Bounce Back From 2020's Dumpster Fi...

Other stocks mentioned: HMC, TM, VALE
1 month ago - InvestorPlace

A controversial Alzheimer's drug that has weighed on Biogen stock this year could ultimately become a major blockbuster within five years, a market research group predicted Tuesday. The post Why A Contr...

2 months ago - Investors Business Daily

Other stocks mentioned: DELL, INTC, MET, MFC
2 months ago - GuruFocus

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Biogen Inc (NASDAQ: BIIB) plans to build a new gene therapy manufacturing facility at its Research Triangle Park manufacturing campuses in North Carolina to support its growing gene therapy pipeline, wi...

2 months ago - Benzinga

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufactu...

2 months ago - GlobeNewsWire

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN ... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Sep 16, 1991
CEO
George Scangos
Employees
9,100
Stock Exchange
NASDAQ
Ticker Symbol
BIIB
Full Company Profile

Financial Performance

In 2020, Biogen's revenue was $13.44 billion, a decrease of -6.49% compared to the previous year's $14.38 billion. Earnings were $4.00 billion, a decrease of -32.06%.

Financial Statements

Analyst Forecasts

According to 33 analysts, the average rating for Biogen stock is "Hold." The 12-month stock price forecast is 286.97, which is an increase of 4.72% from the latest price.

Price Target
$286.97
(4.72% upside)
Analyst Consensus: Hold